Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-12
DOI
10.1186/s13045-022-01242-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
- (2022) A. Filippone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
- (2022) Caicun Zhou et al. LANCET ONCOLOGY
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
- (2022) Yuichiro Doki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
- (2022) Zhi Qi et al. Nature Communications
- CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer
- (2021) Antonio Passaro et al. LANCET ONCOLOGY
- Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
- (2021) Sadna Budhu et al. Cell Reports
- PD‐L1 positively regulates MET phosphorylation through inhibiting PTP1B
- (2021) Shangyun Lu et al. CANCER SCIENCE
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma
- (2021) Lei Guo et al. LIFE SCIENCES
- Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
- (2021) Xiaoming Dai et al. MOLECULAR CELL
- Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
- (2021) Zowi R. Huinen et al. Nature Reviews Clinical Oncology
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression
- (2021) Hong Zhang et al. Advanced Science
- Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
- (2021) Qiaoqi Sui et al. Journal for ImmunoTherapy of Cancer
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
- (2021) Lu Cao et al. Journal of Clinical Medicine
- Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
- (2021) Shangqin Sun et al. Cancers
- The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development
- (2021) Sandra Majo et al. Cancers
- Patient-Derived Cancer Organoids as Predictors of Treatment Response
- (2021) Maikel Verduin et al. Frontiers in Oncology
- Engineering Endogenous Tumor‐Associated Macrophage‐Targeted Biomimetic Nano‐RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo‐Immunotherapy
- (2021) Yupeng Wang et al. ADVANCED MATERIALS
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- (2021) Yujue Wang et al. CANCER CELL
- Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
- (2021) Yan Lan et al. CANCER CELL
- M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
- (2021) Xinyao Qiu et al. CANCER RESEARCH
- Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
- (2021) Kazuhiro Koikawa et al. CELL
- Phase I Study of Stereotactic Body Radiotherapy Plus Nivolumab and Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors
- (2021) Corey C. Foster et al. CLINICAL CANCER RESEARCH
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
- (2021) Benjamin C. Creelan et al. NATURE MEDICINE
- Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways
- (2021) Zhen Xiang et al. ONCOGENE
- Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
- (2021) Janna Krueger et al. PLoS One
- Developmental chromatin programs determine oncogenic competence in melanoma
- (2021) Arianna Baggiolini et al. SCIENCE
- Opposing roles of the immune system in tumors
- (2021) Won Jin Ho et al. SCIENCE
- Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
- (2021) Amaia Martinez-Usatorre et al. Science Translational Medicine
- A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
- (2021) Cecile Geuijen et al. Nature Communications
- Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling
- (2021) Hye Kyung Hong et al. Cancer Medicine
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
- (2021) Salma K. Jabbour et al. JAMA Oncology
- MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
- (2021) Si-Yu Wu et al. Journal for ImmunoTherapy of Cancer
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
- (2021) Yuanyuan Zhang et al. CANCER CELL
- The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
- (2021) Hongzhong Li et al. CANCER CELL
- Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids
- (2021) Vivien Koh et al. CANCER LETTERS
- Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
- (2021) Khiem C. Lam et al. CELL
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
- (2021) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
- (2021) David C Qian et al. LANCET ONCOLOGY
- Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
- (2021) Hussein A Tawbi et al. LANCET ONCOLOGY
- Mutant clones in normal epithelium outcompete and eliminate emerging tumours
- (2021) B. Colom et al. NATURE
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
- (2021) Clemens Hinterleitner et al. Nature Communications
- An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
- (2021) Shuguang Zuo et al. Journal for ImmunoTherapy of Cancer
- Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
- (2021) Qingda Meng et al. Journal for ImmunoTherapy of Cancer
- Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
- (2021) Jayati Chakrabarti et al. Cancers
- Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy
- (2021) Kewen Lei et al. Nature Biomedical Engineering
- Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
- (2020) Haifang Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
- (2020) Rebecca A. Luchtel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-dose vitamin C enhances cancer immunotherapy
- (2020) Alessandro Magrì et al. Science Translational Medicine
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
- (2020) Alok Kumar et al. eLife
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- (2020) M. Marasco et al. Science Advances
- Acquired Resistance to Immune Checkpoint Inhibitors
- (2020) Adam J. Schoenfeld et al. CANCER CELL
- Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study
- (2020) Giovanni Lo Re et al. CYTOKINE
- Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases
- (2020) Lin Zhang et al. Science Translational Medicine
- The Role of PD-1 in Acute and Chronic Infection
- (2020) Jil M. Jubel et al. Frontiers in Immunology
- Master protocols in immuno-oncology: do novel drugs deserve novel designs?
- (2020) Luca Mazzarella et al. Journal for ImmunoTherapy of Cancer
- Characterization of human cancer xenografts in humanized mice
- (2020) Jonathan Rios-Doria et al. Journal for ImmunoTherapy of Cancer
- Ubiquitin C‐terminal hydrolase L1 promotes expression of programmed cell death‐ligand 1 in non‐small‐cell lung cancer cells
- (2020) Rudi Mao et al. CANCER SCIENCE
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Fasting-mimicking diet and hormone therapy induce breast cancer regression
- (2020) Irene Caffa et al. NATURE
- Probiotics in microbiome ecological balance providing a therapeutic window against cancer
- (2020) Nirmala Sehrawat et al. SEMINARS IN CANCER BIOLOGY
- Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation
- (2020) Ning Wang et al. ADVANCED FUNCTIONAL MATERIALS
- Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX‐2 and PD‐L1
- (2020) Suxing Jin et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Challenges and Opportunities for Pancreatic Cancer Immunotherapy
- (2020) Adham S. Bear et al. CANCER CELL
- Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
- (2020) Florida Voli et al. CANCER RESEARCH
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
- (2020) Md Amir Hossain et al. MEDICINAL RESEARCH REVIEWS
- Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
- (2020) Hye-Jung Kim et al. TRENDS IN IMMUNOLOGY
- Toll-Like Receptor 9 Agonists in Cancer
- (2020) Lilit Karapetyan et al. OncoTargets and Therapy
- Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
- (2020) Changrong Wang et al. BIOMATERIALS
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial
- (2020) Makoto Nishio et al. Journal of Thoracic Oncology
- KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity
- (2020) Xizi Jiang et al. Cell and Bioscience
- The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
- (2020) Hui Li et al. Advanced Science
- Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
- (2020) Christophe Glorieux et al. Redox Biology
- Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma
- (2020) Loryn Holokai et al. Cancers
- Physical Plasma-Treated Skin Cancer Cells Amplify Tumor Cytotoxicity of Human Natural Killer (NK) Cells
- (2020) Ramona Clemen et al. Cancers
- Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
- (2019) Wang Manni et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1
- (2019) Emma Eriksson et al. JOURNAL OF IMMUNOLOGY
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
- (2019) Loryn Holokai et al. PLoS Pathogens
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
- (2019) Hyun Lee et al. MOLECULES
- Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
- (2019) Fabrice Barlesi et al. Journal of Thoracic Oncology
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
- (2019) Bo Gong et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
- (2019) Jing Li et al. Future Oncology
- Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis
- (2019) Andrew M Frederickson et al. Immunotherapy
- FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
- (2019) Piao Li et al. JOURNAL OF IMMUNOLOGY
- Development of the Inhibitors that Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
- (2019) Guzik et al. MOLECULES
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
- (2019) Alfredo Addeo et al. Frontiers in Oncology
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
- (2019) Carminia Maria Della Corte et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract
- (2019) Kiichiro Teruya et al. Marine Drugs
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Vitamin C Loaded Poly(urethane-urea)/ZnAl-LDH Aligned Scaffolds Increase Proliferation of Corneal Keratocytes and Up-Regulate Vimentin Secretion
- (2019) Mojgan Moghanizadeh-Ashkezari et al. ACS Applied Materials & Interfaces
- Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer
- (2019) Bin Liu et al. Acta Biomaterialia
- The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
- (2019) Jiajing Cai et al. OncoTargets and Therapy
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
- (2019) Elliot A. Philips et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
- (2019) John Kwon et al. Cancer Discovery
- Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
- (2019) Man-Chin Chen et al. Cancers
- The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis
- (2019) Xiaobo Li et al. Cells
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Serotonin and human cancer: A critical view
- (2018) Denis Sarrouilhe et al. BIOCHIMIE
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells
- (2018) Yang Wang et al. CELL CYCLE
- Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
- (2018) Xiaoqing Zhang et al. Cellular & Molecular Immunology
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
- (2018) LiJun Xu et al. Molecular Oncology
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
- (2018) Mirjana Efremova et al. Nature Communications
- Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
- (2018) Cancer Discovery
- Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes
- (2018) Konrad Gabrusiewicz et al. OncoImmunology
- Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
- (2018) Yiwen Li et al. Journal for ImmunoTherapy of Cancer
- The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
- (2018) Samuel F. Bakhoum et al. CELL
- Role of hypoxia-induced exosomes in tumor biology
- (2018) Chuchu Shao et al. Molecular Cancer
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
- (2018) Anchalee Rawangkan et al. MOLECULES
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma
- (2018) Hailong Ma et al. BRITISH JOURNAL OF CANCER
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Organoid Modeling of the Tumor Immune Microenvironment
- (2018) James T. Neal et al. CELL
- The brain–immune cells axis controls tissue specific immunopathology
- (2018) Maxi Heyner et al. Cellular & Molecular Immunology
- Undo the brake of tumour immune tolerance with antibodies, peptides and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells
- (2018) Wenyi Gu et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
- (2018) Gang Shi et al. MOLECULAR THERAPY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Application of atomic force microscopy in cancer research
- (2018) Xiangying Deng et al. JOURNAL OF NANOBIOTECHNOLOGY
- Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
- (2018) George Fromm et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy of cancers comes of age
- (2017) Hila Yousefi et al. Expert Review of Clinical Immunology
- Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
- (2017) Xun Wang et al. IMMUNOLOGY LETTERS
- Targeting Immune Checkpoints in Cancer Therapy
- (2017) Suzanne L. Topalian JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
- (2017) Daniel Yee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
- (2017) Xiaomei Gong et al. Journal of Thoracic Oncology
- PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
- (2017) Tim Wartewig et al. NATURE
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1
- (2017) Gang Chen et al. NATURE NEUROSCIENCE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
- (2017) J Wang et al. ONCOGENE
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
- (2017) Ming Jing Shen et al. Oncotarget
- The role of exosomal non-coding RNAs in cancer metastasis
- (2017) Jin-Peng Wang et al. Oncotarget
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
- (2017) Howard Y. Li et al. Cancer Immunology Research
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
- (2016) Panpan Zhang et al. CANCER SCIENCE
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
- (2016) Weimin Wang et al. CELL
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
- (2016) Andy J. Minn et al. CELL
- MYC — a thorn in the side of cancer immunity
- (2016) Stefani Spranger et al. CELL RESEARCH
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion
- (2016) Bertram Bengsch et al. IMMUNITY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Organoids: A historical perspective of thinking in three dimensions
- (2016) Marina Simian et al. JOURNAL OF CELL BIOLOGY
- Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy for lung cancer
- (2016) Antonius Steven et al. RESPIROLOGY
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial
- (2016) Joanna E. Long et al. VACCINE
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Targeting immune checkpoints: New opportunity for mesothelioma treatment?
- (2015) Elly Marcq et al. CANCER TREATMENT REVIEWS
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Extracellular vesicles shuffling intercellular messages: for good or for bad
- (2015) Alessandra Lo Cicero et al. CURRENT OPINION IN CELL BIOLOGY
- The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma
- (2015) Natalie Spaccarelli et al. DERMATOLOGIC CLINICS
- Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
- (2015) Timothy J. Daskivich et al. EUROPEAN UROLOGY
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- Human PD-1 binds differently to its human ligands: A comprehensive modeling study
- (2015) Clement Viricel et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
- (2015) Ahmad A. Tarhini et al. Journal of Translational Medicine
- Programmed cell death-1 inhibition in lymphoma
- (2015) Eliza A Hawkes et al. LANCET ONCOLOGY
- Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
- (2015) Abdullah Alsuliman et al. Molecular Cancer
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
- (2015) E. Vacchelli et al. SCIENCE
- New immunotherapies targeting the PD-1 pathway
- (2015) Jordan M. Chinai et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Several immune escape patterns in non-Hodgkin's lymphomas
- (2015) Camille Laurent et al. OncoImmunology
- Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?
- (2015) Guido Kroemer et al. OncoImmunology
- The role of serotonin and its receptors in activation of immune responses and inflammation
- (2014) M. S. Shajib et al. Acta Physiologica
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
- (2014) Shenyou Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
- (2014) Raja Rekik et al. Cellular & Molecular Immunology
- Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients
- (2014) Andreas Pircher et al. LUNG CANCER
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
- (2014) Hatem Soliman et al. PLoS One
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
- (2013) Y. Liu et al. JOURNAL OF NEUROSCIENCE
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
- (2013) Nikolaos Patsoukis et al. MOLECULAR AND CELLULAR BIOLOGY
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Role of the PD-1 Pathway in the Immune Response
- (2012) L. V. Riella et al. AMERICAN JOURNAL OF TRANSPLANTATION
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
- (2011) Kimberly A. Hofmeyer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- PD-L2 is expressed on activated human T cells and regulates their function
- (2011) Nassima Messal et al. MOLECULAR IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
- (2010) Elias A Said et al. NATURE MEDICINE
- PD-1 on dendritic cells impedes innate immunity against bacterial infection
- (2009) S. Yao et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+
- (2009) Karen S. Sfanos et al. PROSTATE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages
- (2008) Hae-Yun Cho et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started